Skip to content
AnalystLens

Idex Quarterly Report for Q1 Ended Mar 31, 2026

Filing Date
Filed April 29, 2026
Period End
March 31, 2026
Security
IEX
One revenue dollarkept$0.14
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jun ’16Jun ’16
  2. Material agreement8-K · Jun ’19Jun ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Leadership change8-K · May ’25May ’25

Summary

Summary of the 10-Q filed April 29, 2026. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation reported first-quarter 2026 net sales of $886.9 milliona, up from $814.3 million a year earlier, with organic sales increasing 5% driven mainly by higher volumes in the Health & Science Technologies segment, particularly in AI-driven data center power and semiconductor markets, along with positive price across segments.

Operating income rose to $172.4 millionb from $142.0 million, and diluted EPS attributable to IDEX was $1.61 versus $1.26. Adjusted diluted EPS, a non-GAAP measure reconciled in the filing, was $2.00 compared with $1.75. Gross margin declined to 44.9% from 45.3%, pressured by price/cost and unfavorable mix.

Cash generation was steady: operating cash flow was $103.7 millionc and free cash flow was $86.0 million, compared with $91.4 million a year earlier. The company returned $76.3 million through share repurchases and $52.8 million in dividends. Borrowings rose to $1.88 billion, mainly from $100.0 million drawn under the $800.0 million Revolving Facility, which had $517.2 million of net availability at quarter-end.

Cash and cash equivalents were $586.2 milliond, and the company remained in compliance with its debt covenants, with an interest coverage ratio of 13.85 to 1 and a leverage ratio of 1.93 to 1. The filing notes that tariffs enacted in 2025 and early 2026 had no material impact on results to date, and management expects to continue mitigating potential unfavorable effects.

The quarter also included $7.4 million of restructuring expenses and asset impairments, including $4.8 million of impairments in the FMT segment, and a $3.7 million gain on a legal settlement. Remaining share repurchase authorization was $849.7 million at quarter-end.

Key Highlights

  1. Net sales rose to $886.9 million from $814.3 million, with organic sales up 5%, led by HST volumes tied to data center power, semiconductor, and space and defense markets.
  2. Diluted EPS attributable to IDEX was $1.61, up from $1.26; adjusted diluted EPS was $2.00 versus $1.75.
  3. Operating income increased to $172.4 million from $142.0 million, while gross margin eased to 44.9% from 45.3%.
  4. Operating cash flow was $103.7 million and free cash flow was $86.0 million, versus $105.7 million and $91.4 million a year earlier.
  5. Total borrowings increased to $1,880.8 million, including $280.1 million outstanding under the Revolving Facility after a $100.0 million draw in the quarter.
  6. The company repurchased $75.6 million of stock and paid $52.8 million in dividends; $849.7 million of repurchase authorization remained.
  7. Restructuring expenses and asset impairments were $7.4 million, including $4.8 million of FMT asset impairments.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2026, Idex kept $0.14.

  1. Revenue$886.9M100.0%
  2. Cost of revenue−$488.8M55.1%
  3. Gross profit$398.1M44.9%
  4. Operating costs−$225.7M25.4%
  5. Operating income$172.4M19.4%
  6. Interest, other & tax−$52.4M5.9%
  7. Net income$120.0M13.5%
Computed from 10-QQ1 FY2026filed April 29, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2026 against Q1 FY2025

Line itemQ1 FY2026Q1 FY2025Change
Revenue$886.90M$814.30M+8.9%
Cost of Revenue$488.80M$445.40M+9.7%
Gross Profit$398.10M$368.90M+7.9%
SG&A Expenses$218.30M$209.40M+4.3%
Operating Income$172.40M$142.00M+21.4%
Net Income$120.00M$95.50M+25.7%
EPS (Basic)$1.61$1.26+27.8%
EPS (Diluted)$1.61$1.26+27.8%
Shares Outstanding (Basic)74.30M75.70M−1.8%
Shares Outstanding (Diluted)74.40M75.80M−1.8%

Frequently Asked Questions

  1. What drove the increase in IDEX's first-quarter 2026 sales?

    Net sales increased 9% overall and 5% organically. The filing attributes the organic growth mainly to higher volumes in the Health & Science Technologies segment, driven by AI-related demand for data center power and semiconductor markets and strength in space and defense, along with positive price across all segments. Favorable foreign currency translation and acquisitions also contributed.

  2. How did profitability change compared with the prior year?

    Operating income rose to $172.4 million from $142.0 million, and net income attributable to IDEX increased to $120.0 million from $95.5 million. Gross margin declined to 44.9% from 45.3%, which management attributes to price/cost pressure and unfavorable mix, partly offset by volume leverage and productivity gains.

  3. How is IDEX funding its share repurchases and dividends?

    In the first quarter, IDEX drew $100.0 million on its Revolving Facility, which was used for general corporate purposes including share repurchases, and repaid $45.3 million. Operating cash flow of $103.7 million also supported returns. Management believes current cash, operating cash flow and Revolving Facility availability will be sufficient for its cash requirements for the foreseeable future.

  4. Are there any significant tariff or legal items investors should note?

    The filing states that tariffs enacted in 2025 and early 2026 did not have a material impact on the company's business or financial statements in the periods presented, and the company will monitor the timing and amount of any tariff refunds. The quarter also included a $3.7 million gain on a patent infringement legal settlement in the FMT segment.

  5. What is the company's balance sheet and credit position?

    At March 31, 2026, IDEX had $586.2 million of cash and cash equivalents, with $514.2 million held outside the United States, and total borrowings of $1,880.8 million. Revolving Facility availability was $517.2 million. The company was in compliance with its covenants, with an interest coverage ratio of 13.85 to 1 against a 3.0 to 1 minimum and a leverage ratio of 1.93 to 1 against a 3.50 to 1 maximum. Credit ratings were BBB (S&P), Baa2 (Moody's) and BBB+ (Fitch).